



14 Nov. 2024

SYN-TECH CHEM. & PHARM. CO., LTD

Industry Forum

Chen-Ming, Hsiao Chairman



生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777



Safe Harbor Notice

- ★ **In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.**
- ★ **We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.**



CONTENTS

Company Brief Introduction

Brief overall
Main Products
DMF/MF Registration Status
Official and Customer Audit Records

Business and Financial Statements

Performance for operation

Strategy in the Future Development & forward-looking

Future strategies and forward-looking



01

Company Brief Introduction

Brief overall

Main Products

DMF/MF Registration Status

Official and Customer Audit Records



Brief overall

● 1982 , Nov. 9 established

- ❑ NT\$ 445,917,130
- ❑ C. M. Hsiao, Chairman
- ❑ 222 employees
- ❑ APIs
 - Animal Drugs
 - Excipient



● ISO

- ❑ ISO 9001
- ❑ ISO 14001
- ❑ ISO 45001
- ❑ PIC/S GMP
- ❑ GDP
- ❑ ISO 14064-1

● Awards Record

- ❑ National Award in Medicine Quality
- ❑ National Award of Outstanding
- ❑ Research and Development Award in Pharmaceutical Technology
- ❑ National Innovation Award
- ❑ Industrial Sustainable Excellence Award
- ❑ Small and medium enterprise Innovation Award
- ❑ National Innovation Award renewal
- ❑ 2024 Net-Zero Industry Competitiveness Superior Award

● All-round development

- ❑ Manpower cultivation
- ❑ Business fields
- ❑ Infrastructure
- ❑ Cooperate with academic units
- ❑ Develop new drugs with other enterprises



Main Products

SYN-TECH CHEM. & PHARM. CO. LTD.

Product 1

Muscle Relaxants

Product 6

Respiratory System Drugs

Product 2

Topical Anesthetic Agents

Product 7

Cardiovascular Agents

Product 3

Digestive System Drugs

Product 8

Chemotherapeutic Drugs

Product 4

Central Nervous System Drugs

Product 9

**Non- Steroidal Anti- Inflammatory
Antipyretics and Analgesics**

Product 5

Excipient and Animal Drugs

Product 10

Others



DMF/MF Registration Status

SYN-TECH CHEM. & PHARM. CO. LTD.

COUNTRY	DMF/MF (APIs)
U.S.A	19
Japan	21
Canada	3
Korea	6
European Union	7
China	3
Others	9



Official Audit Records

SYN-TECH CHEM. & PHARM. CO. LTD.

U.S.A FDA
Number /
Audit : 7

Korea FDA
Number /
Audit : 2

Australia
TGA
Number /
Audit : 2

Mexico
FDA
Number /
Audit : 1

1995

2002

2007

2008

2009

2014

2015

2016

Taiwan FDA
Number /
Audit : 20

Hungary FDA
Number /
Audit : 1

Japan
PMDA
Number /
Audit : 5

EDQM
Number /
Audit : 1



Customer Audit Records

SYN-TECH CHEM. & PHARM. CO. LTD.

Audit year	Number / Audit
2019	25
2020	5
2021	7
2022	11
2023	35
Jan.- Oct., 2024	27



02

Business and Financial Statements


Performance for operation



Revenue of Recent 5 Years

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in million






Product Category Revenue Proportion Between 2024 and 2023 Q3

SYN-TECH CHEM. & PHARM. CO. LTD.


Unit : NT in ten thousand





Sale proportion basis on the Area

SYN-TECH CHEM. & PHARM. CO. LTD.



Data collected form Jan.- Sep., 2024

Revenue Compared Between 2024 and 2023 Q3

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in thousands

Item	Jan.- Sep., 2024	Jan.- Sep., 2023	Differences (%)
Operating revenue	943,393	842,794	12
Gross profit	356,927	314,014	14
Gross profit ratio (%)	38	37	3
Operating profit	257,373	220,200	17
Non- operating income and expenses	120,349	61,714	95
Profit before tax	377,722	281,914	34
Profit after tax	302,008	225,540	34
EPS (in dollar)	6.77	5.06	34



The Differences Between 2024 and 2023 Q3

SYN-TECH CHEM. & PHARM. CO. LTD.

Revenue

- Plant B, which was originally used to support the production of other products, has gradually restored its original product production capacity and integrated manpower to increase equipment utilization.
- Some products that temporarily suspended have been gradually resumed.

Profit

- The gross profit ratio increased due to the increase in operating revenue and changes in the composition of sales products.
- The profit after tax increased due to the increase in claims income of non- operating income .






EPS and Dividend in Recent 5 Years

SYN-TECH CHEM. & PHARM. CO. LTD.

Unit : NT in dollar





03

Strategy in the Future Development & forward-looking

Future strategies and forward-looking



Strategy in the Future Development & forward-looking I

SYN-TECH CHEM. & PHARM. CO. LTD.



- **IMH has been performed Process Validation in the fourth quarter, and it is expected that Japanese pharmaceutical companies will implement Process Validation in the first half year of 2025; AMH can be successfully sold in Japan; it is currently actively obtaining the Master File of DFP.**
- **Optimize the product manufacturing process, automate key steps to provide high-quality and affordable products :**
 1. Research and develop to improve the manufacturing process, plan the automation of key steps. CTT is cooperating with the Development Center for Biotechnology (DCB).
 2. Plant C, D and S have all completed reconstruction and passed the TFDA inspection, Plant E and F have also passed the inspection. In addition to the original products, the production of CMZ, OPS and PEH will be increased.
 3. The main raw material NBOZ has been developed and produced, enabling the production of ZP products.



Strategy in the Future Development & forward-looking II

SYN-TECH CHEM. & PHARM. CO. LTD.

● Carefully select and evaluate suitable new niche APIs for the future development :

In accordance with national needs, products are selected to be manufactured to avoid domestic shortage of drugs. We are still conducting research and development on APB and SBS that are listed in the list of essential drugs. And GSB is currently performing Process Validation.



● Expanding New Business Area :

- Evaluate APIs' key intermediates.
- Develop our business in China market, CTT and AMH.
- Small quantities of specialty APIs, PRX.
- Develop new drugs with other enterprises, GFH.



SYN-TECH CHEM. & PHARM. CO., LTD

Thanks for your attention



生泰合成工業公司
SYN-TECH CHEM & PHARM CO., LTD

Stock Code : 1777